U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 mi... Biopharmaceuticals, Cardiology, FDA Eli Lilly, Boehringer Ingelheim, empagliflozin, JARDIANCE, heart failure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news